Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Researchers at Children's Hospital target immunization
September 17th, 2008
Current study results from the report, 'Domain specificity of the human antibody response to Bacillus anthracis protective antigen,' have been published. According to a study from the United States, "Protective antigen (PA) is the cell surface recognition moiety of the Bacillus anthracis A-B toxin system, and the active immunogenic component in the currently licensed human anthrax vaccine (BioThrax, or AVA). The serum antibody response to the PA protein is polyclonal and complex both in terms of the antibody combining sites utilized to bind PA and the PA-associated epitopes recognized." "We have cloned, sequenced, and expressed a large panel of PA-specific human...
Source: Vaccine Weekly (2008-09-17)
|
